Table 2 Comparison of clinical outcomes between rituximab cohort and control cohort

CASE

Scores median(IQR)

8 (7.25)

6 (2)

0.079

3 (4.5)

3 (2)

0.763

2 (3.25)

2 (2)

0.834

1.5 (1.25)

2 (2)

0.172

0 (1.25)

1 (2)

0.037

Scores differ ± median (IQR)

–

–

–

− 5 (4.5)

− 3 (2)

0.010

− 6.5 (5.5)

− 3 (3)

0.016

− 6.5 (7.3)

− 4 (3)

0.013

− 7 (7)

− 4 (3)

0.007

mRS

Scores median(IQR)

4 (1.25)

4 (1)

0.083

2 (1)

3 (1)

0.270

2 (1)

2 (1.5)

0.771

1 (1.25)

1 (1)

0.532

0.5 (1.25)

1 (2)

0.418

Scores differ ± median (IQR)

–

–

–

− 1 (1)

− 1 (0.5)

0.010

− 2 (10)

− 2 (2)

0.140

− 3 (2)

− 2 (1)

0.043

− 3.5 (2)

− 3 (1)

0.062

MMSE

Scores median (IQR)

14.5 (16.25)

20 (15.5)

0.062

23.5 (11)

23 (10)

0.785

25.5 (7.75)

24 (8)

0.907

26 (6.25)

27 (7)

0.522

28.5 (3)

27 (5)

0.089

Scores differ ± median (IQR)

–

–

–

+ 8 (8.8)

+ 3 (7.5)

0.006

+ 11 (15.5)

+ 4 (13)

0.046

+ 10.5 (16)

+ 5 (14)

0.037

+ 13 (15.3)

+ 7 (14)

0.018

Patient

NPI

Scores median (IQR)

15 (20.5)

9 (10)

0.066

1.5 (4.5)

3 (5.5)

0.532

0 (4)

0 (4)

0.863

0 (2)

0 (3)

0.538

0 (0)

0 (1.5)

0.371

Scores differ ± median (IQR)

–

–

–

− 14 (14.3)

− 6 (10)

0.021

− 13 (16)

− 7 (11.5)

0.044

− 14 (20)

− 8 (11.5)

0.038

− 15 (20.8)

− 8 (11.5)

0.028

Caregiver NPI

Scores median (IQR)

6.5 (5.75)

5 (5)

0.054

1 (3)

2 (3)

0.461

0 (2)

0 (2)

0.785

0 (0.25)

0 (1.5)

0.381

0 (0.25)

0 (1.5)

0.547

Scores differ ± median (IQR)

–

–

–

− 6 (5)

− 2 (4)

0.006

− 5 (7.3)

− 3 (5.5)

0.043

− 6.5 (7.8)

− 4 (5)

0.038

− 6.5 (6.3)

− 3 (5)

0.016